Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine

被引:76
作者
Bashraheel, Sara S. [1 ,2 ]
Domling, Alexander [2 ]
Goda, Sayed K. [3 ]
机构
[1] Antidoping Lab Qatar ADLQ, Prot Engn Unit, Doha, Qatar
[2] Univ Groningen, Dept Pharm, Drug Design Grp, Groningen, Netherlands
[3] Cairo Univ, Chem Dept, Fac Sci, Giza, Egypt
关键词
Precision medicine; Targeted cancer therapy; Superantigen; ADEPT; Checkpoint inhibitors; PROTAC; Antibody drug conjugate; Cancer immunotherapy; ENZYME PRODRUG THERAPY; EARLY RADIOGRAPHIC RESPONSE; MELANOMA BRAIN METASTASES; ANTIBODY-DRUG CONJUGATE; RECOMBINANT INTERLEUKIN-2 THERAPY; ANTI-PD-1 AGENTS NIVOLUMAB; ALPHA-2 INTERFERON THERAPY; POTENT ANTITUMOR-ACTIVITY; CHIMERA PROTAC DEGRADER; RENAL-CELL CARCINOMA;
D O I
10.1016/j.biopha.2020.110009
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Until recently, patients who have the same type and stage of cancer all receive the same treatment. It has been established, however, that individuals with the same disease respond differently to the same therapy. Further, each tumor undergoes genetic changes that cause cancer to grow and metastasize. The changes that occur in one person's cancer may not occur in others with the same cancer type. These differences also lead to different responses to treatment. Precision medicine, also known as personalized medicine, is a strategy that allows the selection of a treatment based on the patient's genetic makeup. In the case of cancer, the treatment is tailored to take into account the genetic changes that may occur in an individual's tumor. Precision medicine, therefore, could be defined in terms of the targets involved in targeted therapy. Methods: A literature search in electronic data bases using keywords "cancer targeted therapy, personalized medicine and cancer combination therapies" was conducted to include papers from 2010 to June 2019. Results: Recent developments in strategies of targeted cancer therapy were reported. Specifically, on the two types of targeted therapy; first, immune-based therapy such as the use of immune checkpoint inhibitors (ICIs), immune cytokines, tumor-targeted superantigens (TTS) and ligand targeted therapeutics (LTTs). The second strategy deals with enzyme/small molecules-based therapies, such as the use of a proteolysis targeting chimera (PROTAC), antibody-drug conjugates (ADC) and antibody-directed enzyme prodrug therapy (ADEPT). The precise targeting of the drug to the gene or protein under attack was also investigated, in other words, how precision medicine can be used to tailor treatments. Conclusion: The conventional therapeutic paradigm for cancer and other diseases has focused on a single type of intervention for all patients. However, a large literature in oncology supports the therapeutic benefits of a precision medicine approach to therapy as well as combination therapies.
引用
收藏
页数:16
相关论文
共 237 条
[1]   Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature [J].
Abdel-Wahab, Noha ;
Safa, Houssein ;
Abudayyeh, Ala ;
Johnson, Daniel H. ;
Van Anh Trinh ;
Zobniw, Chrystia M. ;
Lin, Heather ;
Wong, Michael K. ;
Abdelrahim, Maen ;
Gaber, A. Osama ;
Suarez-Almazor, Maria E. ;
Diab, Adi .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[2]   Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes [J].
Abdollahpour-Alitappeh, Meghdad ;
Lotfinia, Majid ;
Gharibi, Tohid ;
Mardaneh, Jalal ;
Farhadihosseinabadi, Behrouz ;
Larki, Pegah ;
Faghfourian, Babak ;
Sepehr, Koushan Sineh ;
Abbaszadeh-Goudarzi, Kazem ;
Abbaszadeh-Goudarzi, Ghasem ;
Johari, Behrooz ;
Zali, Mohammad Reza ;
Bagheri, Nader .
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (05) :5628-5642
[3]   Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols [J].
Abendroth, A. ;
Noureddine, R. ;
Abramczyk, M. ;
Paul, A. ;
Gerken, G. ;
Schmid, K. W. ;
Markus, P. ;
Schumacher, B. ;
Wiesweg, M. ;
Koehler, J. ;
Markus, M. ;
Mende, B. ;
Dechene, A. ;
Schuler, M. ;
Kasper, S. .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (02) :445-455
[4]   Production of "biobetter" variants of glucarpidase with enhanced enzyme activity [J].
Al-Qahtani, Alanod D. ;
Bashraheel, Sara S. ;
Rashidi, Fatma B. ;
O'Connor, C. David ;
Romero, Atilio Reyes ;
Domling, Alexander ;
Goda, Sayed K. .
BIOMEDICINE & PHARMACOTHERAPY, 2019, 112
[5]   Antibody-drug conjugates: targeted drug delivery for cancer [J].
Alley, Stephen C. ;
Okeley, Nicole M. ;
Senter, Peter D. .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (04) :529-537
[6]   Production of "biobetter" glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment [J].
AlQahtani, Alanod D. ;
Al-mansoori, Layla ;
Bashraheel, Sara S. ;
Rashidi, Fatma B. ;
Al-Yafei, Afrah ;
Elsinga, Philip ;
Domling, Alexander ;
Goda, Sayed K. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 127 :79-91
[7]  
[Anonymous], 2019, F1000RES
[8]  
[Anonymous], ANN ONCOL
[9]  
[Anonymous], INVEST NEW DRUGS
[10]  
[Anonymous], PHARM THER